- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06332391
Paced Heart Rate Acceleration for Cardiac Conditioning (HeartExcel)
A New Pacing Approach for Cardiac Conditioning and Enhanced Cardioprotection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects and protocol: This is a phase II randomized, controlled, prospective clinical trial in subjects with systolic heart failure. It is designed to assess the effect on symptoms, functional, structural, and medical outcomes in response to an atrial paced reproduction of the heart rate exercise pattern delivered regularly over a 6-week period. A single center (University of Iowa) will execute the intervention/sham and subject testing. A separate center (Cleveland Clinic) will perform statistical analysis of deidentified data. Fifty-two subjects will be randomized 1:1 by computer generated code to either the intervention (pacing) arm or the sham arm. The subject, but not researcher, will be blinded to randomization status (single-blind). Analysis of data will be performed in a blinded fashion. Within 2 weeks prior to initiation of pacing vs. sham interventions, baseline testing will be performed including collection and storage of plasma, testing for blood urea nitrogen (BUN), creatinine, N-terminal pro-b-type natriuretic peptide (NT-proBNP), echocardiographic left ventricular (LV) dimensions, left ventricular ejection fraction (LVEF), and quality of life/symptoms by both the Minnesota Living with Heart Failure (MLHF) and the Kansas City Cardiomyopathy Questionnaire (KCCQ), designed for assessment of symptoms over 1 month and 2 week windows, respectively, distance on 6-minute walk, 1 week of pacing device accelerometer-derived activity measures, wearable activity monitor measures, and cardiopulmonary exercise test (CPET) for determination of metabolic equivalents (METs), maximum oxygen consumption (VO2max) and anaerobic threshold (AT) estimated noninvasively, using the rapid incremental exercise test. In addition, starting 1 week prior and continuing through 1 month after the pacing vs. sham intervention, each subject will be provided a wearable activity monitor and their daily activity analyzed as a cofactor. At the end of 2, 4 and 6 weeks of pacing/sham, as well as 3 and 12 months after the intervention, the same outcome measures as at baseline will be collected as well as major adverse cardiovascular events (MACE), weight, medications, and arrhythmias recorded on the subject's implantable cardioverter defibrillator (ICD) or biventricular ICD (BiV/ICD). At the end of the pace/sham period, subject blinding will be assessed by asking subjects if they believe they were in pace or sham group. Collected plasma will be saved for metabolomic testing in year 5 to correlate with findings in mouse models. Outcomes: All tests result analyses will be done by 2 independent clinicians, qualified in specific areas, blinded to the randomization. A reviewer who analyzes a testing parameter will analyze the same parameter for all subjects. Variability between reviewers will be analyzed. The primary endpoint will be change in left ventricular ejection fraction (LVEF) from baseline. Secondary endpoints will include quality of life (QOL) by MLHF score, 6-min walk distance, CPET (including VO2max, metabolic equivalents (METs) achieved, peak power output, total exercise time), daily activity change from baseline and MACE at 3 and 12 months between pacing and sham groups. A "dose-response" analysis of outcomes at 2, 4, and 6 weeks of the intervention vs. sham compared with baseline will be performed. Durability analysis of response at 3 and 12 months will be performed.
The data from all subjects completing at least one pacing vs. sham session will undergo analysis for measures of tolerability (symptoms, maximum achieved pacing rate, appearance of arrhythmias, changes in vital signs and bioimpedance cardiac output) with respect to age, sex, degree, type of cardiomyopathy (ischemic vs. non-ischemic), left ventricular function, NT-proBNP, NHYA class, baseline oxygen consumption (VO2), baseline exertional tolerance, baseline physical activity level as assessed by the ICD of BiV/ICD accelerometer and wearable activity watch, autonomic function as defined by heart rate variability derived from electrocardiogram (ECG) and stored ICD or BiV/ICD data. Hospitalizations, deaths, or other adverse outcomes will similarly be analyzed with respect to baseline data and procedural data such as maximum achieved pacing rate.
For those subjects completing the intervention/sham and follow up visits, the primary endpoint of change in left ventricular ejection fraction will be analyzed. Secondary endpoints will include changes in functional capacity, particularly 6-minute walk, and quality of life indicators as well as MACE with respect to the above study variables.
Descriptive statistics will be used to summarize participant demographic and clinical characteristics at baseline. Categorical variables will be compared using Chi squared tests. For continuous variables, to relax the strict requirement of normality, non-parametric methods for unadjusted comparison will be used (Wilcoxon rank-sum test, also known as the Mann-Whitney two-sample statistic, for comparison of two independent samples. Wilcoxon matched pairs signed-rank test will be used for paired comparisons). For the primary endpoint analysis, a mixed-effects linear regression model will be used to compare the two study arms on the primary outcome of LVEF, with time (2, 4, and 6 wks) and treatment arm (intervention vs. sham) included as fixed effects, and pre-specified covariates of sex (binary male/female) and cardiomyopathy type (binary ischemic/non-ischemic) as random effects. Both stratified randomization by sex and cardiomyopathy type, as well as adjustment for these covariates in the analysis, will be performed. Although often only one or the other technique is sufficient, both are performed here given the well-known confounding effects of sex and cardiomyopathy types in heart failure trials and a desire to be highly rigorous in this regard. An intercept for time of treatment or sham (2, 4, 6 wks) will be included. The significance criteria for the model coefficient corresponding to treatment will be .025 with a one-sided 97.5% confidence interval. Analyses will be conducted on an "intention-to-treat" basis. Estimates and confidence intervals of effect sizes and standard deviation of outcome measures will be presented. Pre-specified subgroup analyses will probe for treatment effect heterogeneity in outcomes based on sex and ischemic cardiomyopathy vs. nonischemic cardiomyopathy. Secondary endpoints will be analyzed in a fashion similar to the primary endpoint analysis. Due to the controlled environment, missing data are expected to be very rare. If such exists, patterns will be evaluated, and multiple imputation performed.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Denice Hodgson-Zingman, MD
- Phone Number: +1 319 384 2915
- Email: denice-zingman@uiowa.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female sex
- Age 18 years or greater
- Available transportation for study visits
- Left ventricular ejection fraction < or = 35% despite at least 3 months guideline-directed medial therapy
- NYHA class II-III heart failure symptoms
- Atrial-lead inclusive implantable cardioverter defibrillator or biventricular defibrillator in place > 3 months
- Intrinsic or biventricular paced QRS duration of <= 120 milliseconds
Exclusion Criteria:
- Age < 18 years
- Inability to ambulate safely
- Congenital or primary valve disease
- Ongoing (not suppressed) atrial arrhythmias
- Left ventricular thrombus
- Severe peripheral arterial disease that limits mobility
- Hospital admission for life-threatening condition (e.g. heart failure, stroke) in the past 3 months
- Major surgery in the past 3 months or anticipated during the period of study
- Ventricular pacing indication in the absence of biventricular pacing
- Life expectancy < 1 year
- Hemodialysis
- Hematocrit < 30%
- Severe chronic lung disease that limits activity or requires oxygen
- Pregnancy
- Implantable cardioverter defibrillator battery longevity < 1 year
- Vulnerable populations such as prisoners and institutionalized individuals
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exercise-similar cardiac pacing
Atrial pacing to replicate exercise heart rate envelope once daily, 3 days per week, over 6 weeks while symptoms and vital signs are monitored and outcome measures assessed.
|
Cardiac pacing using subjects already-implanted cardioverter defibrillator to reproduced exercise heart rate envelope.
|
Sham Comparator: Sham cardiac pacing
Sham pacing to replicate exercise heart rate envelope once daily, 3 days per week, over 6 weeks while symptoms and vital signs are monitored and outcome measures assessed.
|
Simulated (rates selected using programmer but not initiated) cardiac pacing using subjects already-implanted cardioverter defibrillator to reproduced exercise heart rate envelope.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in left ventricular ejection fraction by echocardiogram
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
The change in left ventricular ejection fraction from baseline as determined by echocardiography
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life score on the Minnesota Living with Heart Failure questionnaire
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
Numerical score based on a subject's subjective symptoms and functional status
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
Quality of Life score on the Kansas City Cardiomyopathy Questionnaire
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
Numerical score based on a subject's subjective symptoms and functional status
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
6-minute walk distance
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
Distance on a standard 6-minute walk measured in meters
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
Cardiopulmonary exercise test maximum oxygen consumption
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
V02max (maximum milliliters of oxygen consumed per kilogram of body weight per minute)
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
Cardiopulmonary exercise test metabolic equivalents achieved
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
metabolic equivalents (METs)
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
Cardiopulmonary exercise test peak power output achieved
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
peak power output (watts/kilogram)
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
Cardiopulmonary exercise test total exercise time
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
total exercise time (minutes)
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
daily minutes of sedentary activity
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
CamNtech motion watch 8 average daily minutes of activity in the sedentary range
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
daily minutes of low activity
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
CamNtech motion watch 8 average daily minutes of activity in the low range
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
daily minutes of moderate activity
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
CamNtech motion watch 8 average daily minutes of activity in the moderate range
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
daily minutes of vigorous activity
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
CamNtech motion watch 8 average daily minutes of activity in the vigours range
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
major adverse cardiac events
Time Frame: at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
MACE
|
at baseline versus 2 weeks, 4 weeks, 6 weeks from start of intervention/sham and at 3 months and 12 months after completion of intervention vs. sham.
|
symptom score during the intervention/sham procedure
Time Frame: at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
An aggregate score of a subject's subjective report of shortness of breath, chest pain, palpitations, lightheadedness, each on a scale of 0-10.
Minimum score 0, maximum score 40.
|
at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
maximum achieved pacing rate during the intervention/sham procedure
Time Frame: at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
measured in beats/minute
|
at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
presence of significant arrhythmia during the intervention/sham procedure
Time Frame: at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
binary outcome of 0 (no such arrhythmia) versus 1 (presence of a significant arrhythmia) during each episode of pacing.
A significant arrhythmia refers to either subject-reported symptoms during the arrhythmia, or a change in systolic blood pressure of 20 mmHg from that immediately before the onset of the arrhythmia, or an arrhythmia requiring intervention to terminate.
|
at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
vital signs - systolic blood pressure during the intervention/sham procedure
Time Frame: at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
maximum change in systolic blood pressure (millimeters of mercury) during the intervention/sham period versus the baseline blood pressure immediately before initiation of intervention/sham procedure as measured by plethysmography (standard inflatable blood pressure cuff).
|
at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
vital signs - oxygen saturation in the blood during the intervention/sham procedure
Time Frame: at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
maximum change in blood oxygen saturation (measured as % saturation) during the intervention/sham period versus the baseline immediately before initiation of intervention/sham procedure as measured by pulse oximeter.
|
at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
tolerability - vital signs - cardiac output
Time Frame: at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
maximum change in cardiac output during the intervention/sham period versus the baseline immediately before initiation of intervention/sham procedure as measured by NICaS bioimpedance device.
|
at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
vital signs - cardiac output during the intervention/sham procedure
Time Frame: at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
maximum change in cardiac output (liters/minute) during the intervention/sham period versus the baseline immediately before initiation of intervention/sham procedure as measured by NICaS bioimpedance device.
|
at each intervention/sham procedure - these occur 3 days per week for 6 weeks at the beginning of the study
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Denice Hodgson-Zingman, MD, University of Iowa
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202308349
- R01HL168752 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure, Systolic
-
Central Hospital, Nancy, FranceUnknown
-
Zensun Sci. & Tech. Co., Ltd.Active, not recruitingChronic Systolic Heart FailureChina
-
Zensun Sci. & Tech. Co., Ltd.TerminatedChronic Systolic Heart FailureChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownChronic Systolic Heart FailureChina
-
Hospital Moinhos de VentoTakedaUnknownHeart Failure, Systolic | Systolic Heart Failure | Cardiac FailureBrazil
-
Merck KGaA, Darmstadt, GermanyMerck Ltd.Completed
-
University of NebraskaEli Lilly and Company; Daiichi Sankyo, Inc.Completed
-
Abbott Medical DevicesCompletedSystolic Heart FailureAustralia, Hong Kong, Japan
-
University of CincinnatiCompletedSystolic Heart FailureUnited States
-
GlaxoSmithKlineCompletedHeart Failure, CongestiveKorea, Republic of
Clinical Trials on Exercise-similar cardiac pacing
-
University Hospital of FerraraRecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Left Bundle-Branch Block | Bundle-Branch Block | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Dysfunction | Atrioventricular Block | Heart Failure, Systolic | Ventricular Arrythmia | Heart Failure,Congestive | Bradyarrhythmia | Heart Arrhythmia | Reduced... and other conditionsItaly
-
Duke UniversityBoston Scientific CorporationEnrolling by invitation
-
Boston Scientific CorporationTerminatedHeart Failure | Heart Disease | Left Bundle Branch BlockHong Kong
-
University of Maryland, BaltimoreCompleted
-
Lawson Health Research InstituteUnknownSystolic Heart Failure
-
Heart of England NHS TrustSandwell & West Birmingham Hospitals NHS TrustCompletedHeart Failure, CongestiveUnited Kingdom
-
University of Wisconsin, MadisonCompleted
-
University of Sao Paulo General HospitalUnknown
-
Hunan Provincial People's HospitalRecruitingTachyarrhythmia | Brady-tachy Syndrome | Bradyarrhythmia | Bradycardia; Syncope | AVB - Atrioventricular Block | Tachycardia BradycardiaChina
-
Boston Scientific CorporationCompleted